Eidos Therapeutics Inc

BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.

Akcea Therapeutics

Alnylam Pharmaceuticals

Ionis Pharma

The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

BridgeBio Pharma Inc

BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?

BridgeBio Calls Off Its Acquisition Offer for Eidos Therapeutics

SAN FRANCISCO, Sept.  30, 2019  (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) amyloidosis (ATTR), today announced that an interim analysis of its ongoing Phase 2 open-label extension (OLE) study of AG10 in subjects with symptomatic ATTR cardiomyopathy will be presented in a late-breaking featured science oral presentation at this year’s American Heart Association (AHA) Scientific Sessions.

Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

SAN FRANCISCO, Sept.  19, 2019  (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at 3:00 p.m. EDT in New York, NY.

Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Stoke Therapeutics Inc

Can their share prices continue to climb?

3 New Biotech Stocks That Keep On Soaring

AMAG Pharmaceuticals

Ligand Pharmaceuticals

MannKind

Moderna

Paratek Pharma

Viking Therapeutics

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

AGNC Investment

Discovery

Intrexon

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

News for Eidos Therapeutics Inc Stock (EIDX)